Ignacio Garrido-Laguna, MD, PhD, MBA
Ignacio Garrido-Laguna, MD, PhD, MBA
Program Lead, Early Therapeutics Development
Research Department Chair, Early Therapeutics Development
Chair, Department of Early Therapeutics Development
Program: Early Therapeutics Development
-
Overview
Associations
- Early Therapeutics Development
-
Publications
- Le DT, Folprecht G, Varghese AM, Gutierrez M, Noel M, Trikalinos NA, Chen E, Dayyani F, Davis SL, Ma WW, BasuMallick A, Garrido-Laguna I, Osawa M, O'Brien S, Novosiadly RD, Xu K, Greenawalt DM, Dutta S, Twyman Saint Victor C, Lenz HJ. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. J Immunother Cancer. 2026 Jan.14(1). Pubmedid: 41571299. Pmcid: PMC12829384.